JPWO2022149487A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022149487A5
JPWO2022149487A5 JP2022574004A JP2022574004A JPWO2022149487A5 JP WO2022149487 A5 JPWO2022149487 A5 JP WO2022149487A5 JP 2022574004 A JP2022574004 A JP 2022574004A JP 2022574004 A JP2022574004 A JP 2022574004A JP WO2022149487 A5 JPWO2022149487 A5 JP WO2022149487A5
Authority
JP
Japan
Prior art keywords
ion
group
prostate cancer
trimetyl
cyclohexenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022574004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7769179B2 (ja
JPWO2022149487A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/048082 external-priority patent/WO2022149487A1/ja
Publication of JPWO2022149487A1 publication Critical patent/JPWO2022149487A1/ja
Publication of JPWO2022149487A5 publication Critical patent/JPWO2022149487A5/ja
Application granted granted Critical
Publication of JP7769179B2 publication Critical patent/JP7769179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022574004A 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法 Active JP7769179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021001676 2021-01-07
JP2021001676 2021-01-07
PCT/JP2021/048082 WO2022149487A1 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Publications (3)

Publication Number Publication Date
JPWO2022149487A1 JPWO2022149487A1 (https=) 2022-07-14
JPWO2022149487A5 true JPWO2022149487A5 (https=) 2024-12-09
JP7769179B2 JP7769179B2 (ja) 2025-11-13

Family

ID=82357872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574004A Active JP7769179B2 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Country Status (7)

Country Link
US (1) US20240085400A1 (https=)
EP (1) EP4276456A4 (https=)
JP (1) JP7769179B2 (https=)
CN (1) CN116783484A (https=)
AU (1) AU2021417970A1 (https=)
TW (1) TW202242412A (https=)
WO (1) WO2022149487A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) * 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
US20160025734A1 (en) * 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) * 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
CN108344830B (zh) * 2017-01-22 2020-10-16 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒
US10908162B2 (en) * 2017-10-27 2021-02-02 The Board Of Regents Of The University Of Texas System Methods related to volatile compounds in genitourinary cancers

Similar Documents

Publication Publication Date Title
Monleau et al. Comparison of different extraction techniques to profile microRNAs from human sera and peripheral blood mononuclear cells
Gao et al. Proteomic analysis of acetaminophen‐induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury
Boogaard Use of haemoglobin adducts in exposure monitoring and risk assessment
JP2018509934A5 (https=)
JP2006509186A5 (https=)
Ondruschka et al. Post-mortem in situ stability of serum markers of cerebral damage and acute phase response
Turner et al. Detection of allantoin in clinical samples using hydrophilic liquid chromatography with stable isotope dilution negative ion tandem mass spectrometry
JP2020514689A5 (https=)
US20180299448A1 (en) Colorectal cancer screening method
CN109632780B (zh) 一种检测atp的比色方法及试剂盒
CN103630678A (zh) 男性不育的生物标志物及其应用
AU8474701A (en) Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
Whiteaker et al. Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage
Boogaard et al. Urinary metabolites and haemoglobin adducts as biomarkers of exposure to 1, 3-butadiene: a basis for 1, 3-butadiene cancer risk assessment.
JP2019510974A5 (https=)
Oberpenning et al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?
JPWO2022149487A5 (https=)
Yuan et al. Liver fibrosis associated with potential vinyl chloride and ethylene dichloride exposure from the petrochemical industry
Natarajan et al. Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy
JP2007248395A5 (https=)
JPWO2022072471A5 (https=)
KR101552011B1 (ko) 리소포스파티딜콜린 및 호모시스테인산을 포함하는 난소암 진단용 조성물 및 이를 사용하여 난소암을 진단하는 방법
Silva Dalsasso Joaquim et al. Analytical validation of an in‐house method for adenosine deaminase determination
KR102838354B1 (ko) 전복의 해수 염분 변화 환경 노출 여부 판단용 대사물질 조성물 및 이를 이용한 전복의 해수 염분 변화 환경 노출 여부 판단 방법
WO2014159920A4 (en) A device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers